Bristol-Myers Squibb Co
XETRA:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
XETRA:BRM
|
US |
|
Moelis & Co
NYSE:MC
|
US |
|
Flex Ltd
NASDAQ:FLEX
|
US |
|
3
|
3M Co
XETRA:MMM
|
US |
|
Mosaic Co
NYSE:MOS
|
US |
|
L
|
Legrand SA
DUS:LRC
|
FR |
|
M
|
Molson Coors Beverage Co
F:NY7
|
US |
|
ESR-REIT
OTC:CGIUF
|
SG |
|
P
|
PPG Industries Inc
BMV:PPG
|
US |
|
C
|
Ciena Corp
F:CIE1
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BRM's stock price target?
Price Target
59.46
EUR
According to Wall Street analysts, the average 1-year price target for 
BRM is 59.46 EUR with a low forecast of 34.64 EUR and a high forecast of 72.02 EUR.
What is the Revenue forecast for Bristol-Myers Squibb Co?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is -3%.
What is the Gross Profit forecast for Bristol-Myers Squibb Co?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 8 years is -2%.
What is the Operating Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 8 years is -2%.
What is the Pre-Tax Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 15%.
What is the Net Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 8 years is 7%.